Taking hepatitis B antivirals long term: how to stay on treatment safely and follow up
A practical guide for people taking or starting oral hepatitis B antivirals, covering missed doses, stopping risk, kidney and bone monitoring, pregnancy planning, and follow-up records.
- Audience
- Patients and families
- Published
- 2026-06-26
- Last reviewed
- 2026-06-26
Start with the goal
The usual goal of oral antivirals for chronic hepatitis B is to keep HBV DNA suppressed over time, reduce liver inflammation, and lower risks such as cirrhosis, liver failure, and liver cancer. These medicines are usually not a short course that clears hepatitis B in a few days, and they should not be stopped just because one report looks better.
Common first-line medicines include entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). The choice should be made with a clinician based on kidney function, bone risk, pregnancy plans, prior medicines, HIV coinfection, medicine access, and local guidance.
Ask three questions before building the daily habit
When treatment starts, write down three questions: What time should I take it each day? Should it be taken on an empty stomach or with food? What should I do if I miss one dose? Instructions can differ by medicine and person, so do not copy another person's routine.
Tie the dose to a stable habit, such as bedtime, brushing teeth, or breakfast, and use a pill box, phone reminder, or calendar. Tell the clinician honestly about missed doses at follow-up. Missed doses are not a moral failure; they are a management problem to solve together.
Do not stop or switch medicines on your own
Stopping on your own can lead to HBV DNA rebound and hepatitis flares, especially in people with cirrhosis, previous marked ALT elevation, immune-suppressing treatment, pregnancy, or the postpartum period. If you want to become pregnant, worry about side effects, face cost pressure, or see undetectable virus on a report, talk with the clinician first.
If stopping or switching is truly needed, the clinician will usually arrange closer ALT, HBV DNA, and liver-function monitoring and explain what symptoms or results should trigger earlier contact. Do not use the idea that long-term medicine harms the body as a reason to stop by yourself; real risks should be assessed with specific tests.
Understanding kidney and bone monitoring
TDF is more often discussed in relation to kidney function and bone mineral density. TAF or entecavir may be considered for some people with kidney or bone risk, but no medicine is best for everyone. Hepatitis B Online describes kidney safety assessment before and during TDF therapy, such as serum creatinine, serum phosphate, and urine glucose or protein testing.
If you are older, have chronic kidney disease, diabetes, high blood pressure, osteoporosis, long-term use of medicines that affect the kidneys, or past abnormal kidney tests, tell the clinician before starting treatment. You do not need to order or interpret every test on your own, but you should know what to check next, when to check it, and whom to contact if results are abnormal.
Bring a simple medicine record to visits
One table is enough: medicine name and dose, start date, usual dosing time, missed-dose dates, any pauses, other prescription medicines, over-the-counter medicines, supplements, alcohol use, kidney function and phosphate results, HBV DNA, ALT/AST, bone pain or fracture history, pregnancy plans, and immune-suppressing treatment plans.
At follow-up, ask directly: Is my viral load falling as expected? Are liver tests stable? Do I need kidney function, urine testing, phosphate, or bone-density monitoring? Is this medicine still appropriate for my kidneys, bones, and pregnancy plans? What is the next follow-up date?
When to contact a clinician quickly
Contact a clinician quickly for jaundice, very dark urine, marked fatigue, abdominal swelling, vomiting blood or black stools, confusion, severe nausea or vomiting, clearly reduced urination, or abnormal liver tests after several missed doses or a treatment stop. If you are planning pregnancy, already pregnant, about to start chemotherapy, or starting immune-suppressing medicines, do not wait for a routine visit to mention it.
Action checklist
Write the medicine name, dose, and dosing time on your phone and pill box. Set a daily reminder. Record missed doses and side effects honestly. Do not stop, switch, or reduce the dose on your own. Bring HBV DNA, ALT/AST, kidney function, urine testing, and phosphate results to follow-up. Tell the clinician early about kidney disease, osteoporosis, pregnancy plans, or immune-suppressing treatment. Confirm the next follow-up date and urgent-contact conditions.
References
WHO 2024 Chronic Hepatitis B Guidelines
World Health Organization · accessed 2026-06-26
Hepatitis B Online Choosing an Initial HBV Treatment Regimen
University of Washington Hepatitis B Online · accessed 2026-06-26
Hepatitis B Online Monitoring Persons On and Off HBV Therapy
University of Washington Hepatitis B Online · accessed 2026-06-26
AASLD Hepatitis B Guidance
American Association for the Study of Liver Diseases · accessed 2026-06-26
Continue Reading
View all in this topicIf this article is relevant to your situation, these articles in the same topic can help you keep organizing questions and next steps.
When hepatitis B has progressed to cirrhosis: follow-up, complications, and emergency signs
A practical guide for people told they have cirrhosis or advanced fibrosis: antiviral care, cancer surveillance, varices, ascites, medicine safety, nutrition, and emergency signs.
Antiviral treatment and monitoring: what to prepare before each hepatitis B visit
A visit-preparation checklist for chronic hepatitis B care, including HBV DNA, ALT, liver cancer surveillance, medicine adherence, and questions to ask.
Before chemotherapy, immunosuppression, or biologics: do not miss hepatitis B reactivation risk
What HBV reactivation means, which treatments should trigger screening, and what to ask before cancer or immune-suppressing therapy starts.